Hi-Risk/Recurrent/Advanced PCa Video Chat, May 14, 2024

Hi-Risk/Recurrent/Advanced PCa Video Chat, May 14, 2024

Hi-Risk/Recurrent/Advanced PCa Video Chat, May 14, 2024

AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostics.
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime!
Join our other free and drop in groups:
Editor’s Pick: Metastatic prostate cancer in addition to metastatic melanoma — at age 50 (bn)
Topics Discussed
He’s 76, hasn’t had a PSMA scan, so maybe not so fast with that surgery — plus he’s in bondage to a restrictive insurance plan; guide the surgery/radiation choice with the online MSK nomogram; treatment for his metastatic melanoma revealed metastatic prostate cancer — at age 50;  low hemoglobin keeps him from a clinical trial; why’d doc prescribe Lynparza — you should always ask a doc why; bad to worse when he switches to darolutamide; Orgovyx more tolerable than Lupron?; don’t sweat a 0.01 PSA rise;  PSA near zero but PSMA scan can still have value — if insurance will pay; doc balks at drug to reduce testosterone flare; women’s libido-boosting drug Vyleesi may also work for men on ADT — Dr. E putting a study together.
Chat Log
Bill Franklin · 6:27 PM
Daniel, this is where the chat appears.
Unknown · 6:28 PM
https://www.prostatecancerpromise.org/?utm_campaign=ANCAN&utm_medium=link&utm_source=Webinar
Unknown · 6:29 PM
Free genetic test
Julian – Houston · 6:32 PM
https://www.mskcc.org/nomograms/prostate
John A · 6:48 PM
I ran Daniel’s nomogram with what info I have.   Daniel you should do it.
Julian – Houston · 6:56 PM
https://www.mskcc.org/nomograms/prostate
Mark Thompson · 7:00 PM
Thank you all for having this support group. Unfortunately, I am dealing with sacrum pain and just fatigue this evening. Thank you. Mark Thompson Rehoboth Beach DE.
AnCan  – rick · 7:15 PM
Great point, Capt!!!
Michael McCabe · 7:18 PM
so far i prefer firmagon
Matt M · 7:19 PM
Thanks guys, really appreciate the support and advice!
daniel straub · 7:32 PM
John A: This is Dan and your previous chat indicated that I “should do it”… my nomogram indicates 50-80% high grade prostrate cancer.  Are you indicating I should do the surgery removal?
AnCan  – rick · 7:33 PM
Daniel – please use this link for PROMISE. It is likely to be much quicker than via KP. https://www.prostatecancerpromise.org/?utm_campaign=ANCAN&utm_medium=link&utm_source=Webinar
Talking Estradiol (E2) for Recurrent and Advanced Prostate Cancer: Wassersug et al

Talking Estradiol (E2) for Recurrent and Advanced Prostate Cancer: Wassersug et al

Talking Estradiol (E2) for Recurrent and Advanced Prostate Cancer: Wassersug et al

AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostics.  Sincere apologies to all for failing to record our May 6 Group. It was totally a platform fault and not down to AnCan. As regulars are aware. this is a very rare event. AnCan hopes this session might make up for it.

Estrogen in its various forms has long been used as a primary and secondary means of managing prostate cancer. Primarily it can be used in place of an LHRH ADT drug. In its secondary capacity, it can be employed in addition to an LHRH drug to help men cope with side effects arising from lack of estrogen caused by the LHRH drug. These side effects include hot flashes and weakening bone density. Today Estradiol (E2) is considered to be a safe treatment when used as a skin patch or gel versus its original application in pill form that carried significant cardiovascular risks.

The foremost peer expert on the use of estrogen to manage prostate cancer is Richard Wassersug, Ph.D, author of Androgen Deprivation Therapy: An Essential Guide for Prostate Cancer Patients and Their Loved Ones that is now in its 3rd Edition https://connect.springerpub.com/content/book/978-0-8261-8403-0. Richard is also an AnCan Advisory Board Member.

In this 60 +minute discussion, Dr. Wassersug talks with two patients about using estradiol. One has used for primary control for 17 years, and the other just started using an Estradiol patch to control side effects alone. He is also joined by AnCan advanced PCa peer Moderators, Dr. John Antonucci and Rick Davis.

Rechallenging advanced disease with enzalutamide after Pluvicto is mentioned towards the end. Dr. Wassersug has since clarified that he favors rechallenging advanced disease with previous therapies after some form of radiation based on the abscopal effect. The use of enzalutamide in this context is not based on trial evidence.

AnCan asks that you first read Richard Wassersug’s book before reaching out to him. AND… Dr. Wassersug urges you to spend as much time exercising today as you have taken to watch this video!

To watch a previous session with Dr. Wassersug on this topic go to https://ancan.org/estrogen-based-hormone-therapy-treating-prostate-cancer/

Hi-Risk/Recurrent/Advanced PCa Video Chat, May 14, 2024

Hi-Risk/Recurrent/Advanced PCa Video Chat, April 23, 2024

Hi-Risk/Recurrent/Advanced PCa Video Chat, April 15, 2024

AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostics.
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime!
Join our other free and drop in groups:
Editor’s Pick: What do medical medical marijuana and estradiol (E2) have in common? … cardiovascular risks (rd)
Topics Discussed
Is this Newbie getting enough radiation for his high risk situation?; darolutamide monotherapy or maybe a drug holiday?; ARX517 trial – PSMA antibody drug conjugate that carries cytotoxic payload; addressing sleep issues; otc CBN; medical marijuana comes with cardiovascular risks; switching your provider for cause; estradiol and phytoestrogens; early success with AR degrader ARV766; delaying Pluvicto #3 and considering PARP-i; is it a flare or progression?; fenbendazole
Chat Log
Hi-Risk/Recurrent/Advanced PCa Video Chat, May 14, 2024

Hi-Risk/Recurrent/Advanced PCa Video Chat, April 15, 2024

Hi-Risk/Recurrent/Advanced PCa Video Chat, April 15, 2024

 

AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostics.
View AnCan’s patient-centered selection of papers and presentations from ASCO GU 2024, one of the top conferences on prostate cancer treatment:  https://youtu.be/YweU8hjA0Lw 
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/          Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups: Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/       Veterans Healthcare Navigation… 4th Thursday @ 8.00 pm Eastern https://ancan.org/veterans/
Editor’s Pick: Two younger men face challenging treatment but it’s the older man with the young wife who yearns for his testosterone! (rd)
Topics Discussed
SoC not offered to ‘young’ man with recurrent disease; testosterone replacement therapy; another young Gent with mHSPC needs a GU med onc QB; blood work returning to normal; drug holiday coming up; are glucocorticoids carcinogenic in the short or long run?; high risk diagnosis needs more investigation before treatment decision; there are solutions to ED; successful Tx continues as T returns.
Chat Log
  • Richard Tolbert

    sent: 5:30 PM

    The Patient Advocate Foundation, Co-Pay Relief Fund (CPR) Prostate Cancer, Metastatic Prostate Cancer and Prostate Cancer Health Equity are now open. Contact 866.512.3861. Email for portal: The Patient Advocate Co-Pay email portal: https://copays.org/#login

    sent: 6:04 PM

    Mark. Can’t find you to reply just to you. I am in bed because I had knee replacement surgery 3 weeks ago. Much more comfortable. I actually find my bedroom is the most comfortable place for these meetings.

    Richard Tolbert

    sent: 6:09 PM

    Jeff, it’s Richard Tolbert. Don’t understand the problem. Good luck with your recovery. My wife is at a crossroads with her knee pain, bone on bone. Will need knee replacement surgery in the near future.

  • sent: 6:11 PM

    Mark asked me in a private message why I was in bed, and if it was due to painful bone metastasis.

    Adam Albarado

    sent: 6:27 PM

    Thanks for the discussion and advice guys!

    AnCan – rick

    sent: 6:30 PM

     

    sent: 6:30 PM

    We are here for you Adam

    AnCan – rick

    sent: 6:31 PM

    THOMAS Matica

    sent: 6:40 PM

    From the Prostate Cancer Foundation “How Bipolar Androgen Therapy Works” https://www.pcf.org/c/how-bipolar-androgen-therapy-works/ Quite the see-saw therapy. Has anyone heard of this or been treated with it? Thomas

    Peter Kafka – Maui

    sent: 6:49 PM

    Dr. Ming Zhou – Dept. of Anatomic & Clinical Pathology, Tufts University School of Medicine. 800 Washington St, Box 802, Boston, MA 02111 – Have the pathology slides sent there for a second opinion on pathology.

    Peter Kafka – Maui

    sent: 6:50 PM

    Johns Hopkins second opinion on pathology: pathology.jhu.edu

    AnCan – rick

    sent: 6:50 PM

     

    Adam Albarado

    sent: 7:03 PM

    ☝️

    sent: 7:04 PM

    I have my PSA test tomorrow and I feel it will be lower than the last test at 0.09.

    THOMAS Matica

    sent: 7:09 PM

    Good Night, All……………..Thomas

    Julian – Houston

    sent: 7:11 PM

    good night all – another great discussion!!!

    AnCan – rick

    sent: 7:13 PM

    He’s in Panama City, PANAMA, Adam!!!

    Adam Albarado

    sent: 7:14 PM

    Ha! Yeah…the same but different.

    Adam Albarado

    sent: 7:15 PM

    That does explain the pulsing music though.

Hi-Risk/Recurrent/Advanced PCa Video Chat, May 14, 2024

Hi-Risk/Recurrent/Advanced PCa Video Chat, April 1, 2024

Hi-Risk/Recurrent/Advanced PCa Video Chat, April 1, 2024

AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Myovant, Telix & Blue Earth Diagnostics.

View AnCan’s patient-centered selection of papers and presentations from ASCO GU 2024, one of the top conferences on prostate cancer treatment: • ASCO GU 2024 conference highlights https://www.youtube.com/watch?v=YweU8hjA0Lw&t=2s

AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.

AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.

AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download

AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.

All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/

Join our other free and drop in groups: Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/ Veterans Healthcare Navigation… 4th Thursday @ 8.00 pm Eastern https://ancan.org/veterans/

Editor’s Pick: Androgen Receptor degrader ARV766 arrives ahead of its webinar later this year (rd)

Topics Discussed

Diagnosed at 52 and concerned about recurrence at 61; pulse and bloods back to normal – was it the RT?; Metastatic Directed Therapy is not for everyone; starting AR degrader ARV766 trial; issues arising from RT proctitis and hemorrhoids; military vs civilian medical care; questioning pembrolizumab and its toxicity with TMB of 8.6?; abscopal effect from RT with Keytruda

Chat Log